OncoMatch

OncoMatch/Clinical Trials/NCT05618821

Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer

Is NCT05618821 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Indocyanine Green Tracer for gastric cancer.

Phase 2RecruitingFujian Medical UniversityNCT05618821Data as of Jun 2026Location: China

Treatment: Indocyanine Green TracerPatients with resectable remnant gastric cancer were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection ICG group and non-injection ICG group.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Indocyanine Green Tracer

Cancer type

Gastric Cancer

Disease stage

Required: Stage N- (AJCC Seventh Edition)

Excluded: Stage DISTANT METASTASIS

cT1-4a, N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

Cannot have received: neoadjuvant chemotherapy

History of previous neoadjuvant chemotherapy

Cannot have received: radiotherapy

History of previous neoadjuvant...radiotherapy

Lab requirements

Cardiac function

ASA class I to III; FEV1<50% of the predicted values excluded; history of unstable angina or myocardial infarction within past six months excluded

ASA (American Society of Anesthesiology) class I to III; FEV1<50% of the predicted values; History of unstable angina or myocardial infarction within the past six months

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05618821 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior neoadjuvant chemotherapy, radiotherapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage N- is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify